灿菲特生物制药 CANF 深 沪
等待开盘 02-14 09:30:00 美东时间
4.2715
+0.022
+0.51%
华盛通- 最 高4.85
- 今 开4.26
- 成交量 4188股
- 最 低 0.1678
- 昨 收 4.25
- 总市值 11.61万
- 52周最高 4.85
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 0.1678
- 委 比 90.48%
- 总股本 2.72万
- 历史最高 141.90
- 量 比 0.75
- 振 幅 110.17%
- 历史最低 0.1678
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Can-Fite Secures Brazilian Patent for Erectile Dysfunction Drug Candidate CF602
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today it received a
2025-11-20 20:04
Nasdaq Down 1%; Medtronic Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-11-19 01:53
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more th...
2025-11-18 22:55
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite BioPharma's VP of Business Development, Dr. Sari Fishman, will present updates on the Phase IIa study of Namodenoson for advanced pancreatic cancer at the BIO 2025 Convention. The trial, led by Prof. Salomon Stemmer, has enrolled 50% of its target patients and shown a favorable safety profile.
2025-06-16 13:00
EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
EF Hutton analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.
2024-09-24 22:27
EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
EF Hutton analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.
2024-08-31 03:10
Can-Fite BioPharma 1H EPS $(0.00), Same YoY; Revenue $316K Down From $392K YoY
Financial Results Revenues for the six months ended June 30, 2024 were $0.32 million compared to revenues of $0.39 million for the same period in 2023. Revenues for the six months ended June 30, 2024 and June 30, 2023 comprised of recognition of a portion of advance payments received under distribut...
2024-08-29 20:21
